213 related articles for article (PubMed ID: 15349869)
1. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders.
Letendre SL; McCutchan JA; Childers ME; Woods SP; Lazzaretto D; Heaton RK; Grant I; Ellis RJ;
Ann Neurol; 2004 Sep; 56(3):416-23. PubMed ID: 15349869
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people.
Vitiello B; Goodkin K; Ashtana D; Shapshak P; Atkinson JH; Heseltine PN; Eaton E; Heaton R; Lyman WD
AIDS; 2007 Jul; 21(11):1415-22. PubMed ID: 17589187
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children.
Jeremy RJ; Kim S; Nozyce M; Nachman S; McIntosh K; Pelton SI; Yogev R; Wiznia A; Johnson GM; Krogstad P; Stanley K;
Pediatrics; 2005 Feb; 115(2):380-7. PubMed ID: 15687448
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.
Ellis RJ; Hsia K; Spector SA; Nelson JA; Heaton RK; Wallace MR; Abramson I; Atkinson JH; Grant I; McCutchan JA
Ann Neurol; 1997 Nov; 42(5):679-88. PubMed ID: 9392566
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.
Antinori A; Perno CF; Giancola ML; Forbici F; Ippolito G; Hoetelmans RM; Piscitelli SC
Clin Infect Dis; 2005 Dec; 41(12):1787-93. PubMed ID: 16288405
[TBL] [Abstract][Full Text] [Related]
7. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
[TBL] [Abstract][Full Text] [Related]
8. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
[TBL] [Abstract][Full Text] [Related]
9. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.
McArthur JC; McDermott MP; McClernon D; St Hillaire C; Conant K; Marder K; Schifitto G; Selnes OA; Sacktor N; Stern Y; Albert SM; Kieburtz K; deMarcaida JA; Cohen B; Epstein LG
Arch Neurol; 2004 Nov; 61(11):1687-96. PubMed ID: 15534180
[TBL] [Abstract][Full Text] [Related]
10. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
11. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
Manavi K; Scott G
Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
[TBL] [Abstract][Full Text] [Related]
12. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings.
Cherner M; Ellis RJ; Lazzaretto D; Young C; Mindt MR; Atkinson JH; Grant I; Heaton RK;
AIDS; 2004 Jan; 18 Suppl 1():S27-34. PubMed ID: 15075495
[TBL] [Abstract][Full Text] [Related]
13. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR;
J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119
[TBL] [Abstract][Full Text] [Related]
15. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
[TBL] [Abstract][Full Text] [Related]
16. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.
Gibbie T; Mijch A; Ellen S; Hoy J; Hutchison C; Wright E; Chua P; Judd F
HIV Med; 2006 Mar; 7(2):112-21. PubMed ID: 16420256
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.
Mellgren A; Price RW; Hagberg L; Rosengren L; Brew BJ; Gisslén M
Neurology; 2007 Oct; 69(15):1536-41. PubMed ID: 17923616
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.
Larru B; de Mendoza C; Bellón JM; de José MI; Mellado MJ; Soriano V; Muñoz-Fernandez MA; Ramos JT
BMC Infect Dis; 2007 Jun; 7():55. PubMed ID: 17559687
[TBL] [Abstract][Full Text] [Related]
19. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
[TBL] [Abstract][Full Text] [Related]
20. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
Metzner KJ; Allers K; Rauch P; Harrer T
AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
